Details

Autor(en) / Beteiligte

• Ghofrani, Hossein-Ardeschir
• D'Armini, Andrea M
• Grimminger, Friedrich
• Hoeper, Marius M
• Jansa, Pavel
• Kim, Nick H
• Mayer, Eckhard
• Simonneau, Gerald
• Wilkins, Martin R
• Fritsch, Arno
• Neuser, Dieter
• Weimann, Gerrit
• Wang, Chen

Titel

Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension

Ist Teil von

• The New England journal of medicine, 2013-07, Vol.369 (4), p.319-329

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2013

Quelle

MEDLINE

Beschreibungen/Notizen

• In this trial, 261 patients with chronic thromboembolic pulmonary hypertension were assigned to placebo or to the soluble guanylate cyclase stimulator riociguat. At 16 weeks, riociguat had significantly improved the 6-minute walk distance and pulmonary vascular resistance. Chronic thromboembolic pulmonary hypertension is characterized by obstruction of the pulmonary vasculature by residual organized thrombi, 1 leading to increased pulmonary vascular resistance, progressive pulmonary hypertension, and right ventricular failure. 2 , 3 Patients with chronic thromboembolic pulmonary hypertension have a poor prognosis unless they receive treatment early. 4 Pulmonary endarterectomy is the standard treatment for chronic thromboembolic pulmonary hypertension and is the only potentially curative treatment. 5 However, surgery is not an option for all patients; some patients are ineligible for surgery owing to the occlusion of distal vessels or coexisting conditions, some decline surgery, and some do not have access to expert surgical . . .